← brief for 2026-09-30 · Slowing decline

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.

Paper No results yet Peer reviewed

Key takeaways

This review gives practical advice for doctors in Australia on using semaglutide. It notes that this drug slowed kidney decline by 24% in a major trial. The panel discusses how to fit this drug into current care plans. It is a guide for doctors, not a new study with fresh results.

Who did this work

Pedagogos E · Chen R · Nelson A · Badve S · Rasalam R · MacIsaac R

Source

Paper · PubMed, the drug frontier · 2026 Sep 30
https://pubmed.ncbi.nlm.nih.gov/42813318/